Ranolazine (Ranexa) Pharmacology Podcast

Ranolazine, marketed as Ranexa, serves primarily as a treatment for chronic angina, though it remains rarely prescribed in clinical practice. The medication functions by blocking inward sodium channels in cardiac tissue, which subsequently lowers intracellular calcium levels and reduces cardiac oxygen demand. Despite its efficacy, clinicians must exercise caution due to a complex profile of drug interactions, particularly involving CYP3A4 inhibitors and inducers, as well as P-glycoprotein and OCT inhibition. Notable risks include QTc interval prolongation and potential concentration increases for medications like metformin and digoxin. Given these significant pharmacokinetic considerations and the availability of more common alternatives like beta-blockers and calcium channel blockers, Ranolazine requires careful monitoring and thorough drug interaction screening before administration. It is not intended for acute relief of chest pain, distinguishing it from sublingual nitroglycerin.